title: Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.
abstract: OBJECTIVE
  To investigate the efficacy of reducing the drop-skin contact to prevent dermatologic side effects of bimatoprost 0.03% topical therapy.
  
  
  METHODS
  Prospective, randomized, single-blinded, internally controlled study.
  
  
  METHODS
  Enrolled subjects started bimatoprost 0.03% therapy once at night in both eyes and were instructed to wipe selectively only one eye (eye 1) with an adsorbent pad during and after drops administration for four months. The fellow eye acted as the internal control. Eyelash growth, regional skin hypertrichosis, and pigmentation on the periocular skin were assessed at baseline and during the four months of follow-up.
  
  
  RESULTS
  A lower incidence of eyelash growth and skin pigmentation in the inferonasal pericanthal region were observed in eye 1. The incidence of pigmentation in the inferotemporal skin region and skin hypertrichosis were similar in the two eyes.
  
  
  CONCLUSIONS
  The reduction of the drop-skin contact affects the regional incidence and the extent of dermatologic skin changes that are related to bimatoprost 0.03% topical therapy.
authors.affiliation: Department of Ophthalmology, University of Tor Vergata, Rome, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Centofanti
authors.forename: Francesco
authors.initials: F
authors.lastname: Oddone
authors.forename: Sergio
authors.initials: S
authors.lastname: Chimenti
authors.forename: Lucia
authors.initials: L
authors.lastname: Tanga
authors.forename: Luigi
authors.initials: L
authors.lastname: Citarella
authors.forename: Gianluca
authors.initials: G
authors.lastname: Manni
mesh_terms: D000328:Adult; D000368:Aged; D000577:Amides / Q000009:adverse effects* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069580:Bimatoprost; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004209:Disposable Equipment; D005140:Eyelashes / Q000187:drug effects; D005141:Eyelid Diseases / Q000139:chemically induced / Q000517:prevention & control*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy; D006201:Hair Diseases / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced / Q000517:prevention & control*; D007429:Intraocular Pressure / Q000187:drug effects; D008055:Lipids / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use; D009885:Ophthalmology / Q000379:methods; D011446:Prospective Studies; D016037:Single-Blind Method; D017592:Skin Care / Q000295:instrumentation*; D012880:Skin Pigmentation / Q000187:drug effects
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D009883:Ophthalmic Solutions; D003008:Cloprostenol; D000069580:Bimatoprost